Basilea receives further USD 13 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam

US BARDA awarded Basilea USD 13.3 million to continue the development of Basilea’s novel oral antibiotic ceftibuten-ledaborbactam.

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.